Protinhi Therapeutics develops novel drugs acting as protease inhibitors to treat a wide range of illnesses. Currently we focus on viral infectious diseases, including dengue fever, Zika, West Nile virus, chikungunya and corona virus. Our aim is to make those drugs available as new medication for patients in need of effective treatment.
We have discovered and patented a novel class of Geminoid protease inhibitors that target membrane bound proteases, such as viral proteases and metalloproteases. Our Geminoid synthesis platform combines a variable element for optimal selectivity and a variable element for localised or targeted delivery to the disease area. Our aim is to develop high quality candidate drugs to preclinical or early clinical stage and subsequently out-license or co-develop these with pharma or biotech partners.